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Cardiac and vascular diseases represent one of the most substantial medical areas for the applications of
regenerative medicine. Despite advances in endovascular repair, surgical intervention, and disease management,
atherosclerosis and heart failure continue to be prominent health problems. This report analyzes the regenerative
medicine treatment opportunities in both cardiovascular and peripheral vascular repair, examining the treatment
opportunities for tissue-engineered vascular grafts as well as cell-based therapies. U.S. hospital discharge data were
used to generate a detailed estimate of the relative target populations for cardiac and vascular disease. Gap analyses
were performed for vascular access, small caliber vascular grafts, and cell-based therapies for revascularization and
heart failure. The analysis compared current alternatives, gaps in medical need, and what a tissue-engineered or
regenerative alternative should achieve for optimum medical and commercial feasibility. Although the number of
coronary bypass grafts vastly outnumbered peripheral grafts, a detailed consideration of re-grafts and the success of
first grafts combined with gap analysis (GAP) leads us to conclude that peripheral vascular disease is the more
commercially feasible and attractive target opportunity for engineered small caliber grafts for the foreseeable future.
Cardiac bypass would need substantial long-term clinical experience, which could be a significant hurdle. Vascular
access, often regarded as a first-in-man indication, is an excellent opportunity for an engineered graft as an alter-
native to arteriovenous fistula that could overcome complications associated with a prosthetic graft. The GAP also
suggests that for heart failure, cellular therapies should link near-term changes in repair, such as improvement in
cardiac output and reduced scarring with limiting progression of the disease, reducing the need for complex
pharmacologic management, and reducing rates of hospitalization. Naturally, researchers must determine where
their technology and know-how can be applied most effectively, but it is clear from our analysis that an astute
strategy in the use of science and technology will be important to successful translation in this space.
Introduction
In 2006, cardiovascular disease accounted for 1 in every2.9 deaths in the United States.1 Great strides in medical
devices, such as drug-eluting stents, medicines like tissue
plasminogen activator, and a wealth of surgical experience
combined with minimally invasive procedures have greatly
improved morbidity and the possibility of surviving an acute
myocardial infarction (AMI). In peripheral vascular disease,
endovascular prostheses have lowered the operative risk in
treating life-threatening abdominal aortic aneurysms (AAA)2
and balloon angioplasty and stents can be used to open
atherosclerotic vessels. These advances also mean that cur-
rent and future interventions made to the heart and vascu-
lature will be asked to withstand tests of time, restore lasting
function without undue complications or the need for re-
intervention and ideally, prevent the worsening of the dis-
order or disease. Regenerative therapy seems like a natural
candidate to fulfill those needs, both for vascular and heart
disease. Based on incidence, cardiovascular disease stands
1The McGowan Institute of Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
2Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
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out as one of the most abundant areas of therapeutic op-
portunity for regenerative medicine.3,4
It has long been recognized that tissue engineering could
play an important role in vascular disease. For example, for
vascular grafts, the seminal work of Weinberg and Bell,5
fabricating vascular grafts from cell-seeded resorbable scaf-
folds6,7 the innovation of cell-produced grafts by Auger and
colleagues,8,9 employing biological matrices as acellular
grafts remodeled in vitro pioneered by Badylak and co-
workers,10,11 and many other efforts laid the foundation for
the promising work of today. Regenerative medicine is
currently at a point of designing and producing numerous
first-generation products, many to treat cardiovascular and
peripheral vascular disorders. For example, the ground
breaking clinical work of Shinoka and colleagues12 has con-
tributed critical understanding of vascular graft remodeling
in humans.13 Innovation continues in biomaterial design
(reviewed by Ravi and Chaikof14) using bone marrow as a
cell source (reviewed by Critser et al.15) as well as finding
better ways to deal with problems of graft integration,16
stenosis17 (reviewed by Duncan and Breuer18), and fabrica-
tion.19,20 Commercial efforts have also progressed; McAllister
and colleagues (Cytograft, Inc.) have advanced a cell-
produced vascular graft to the clinic with promising re-
sults21,22 and Dahl and colleagues (Humacyte, Inc.) have
devised an innovative commercial process for large-scale
construction of cell-based vascular grafts starting with a re-
sorbable scaffold.4 There seems little doubt that the tech-
nology and innovative talent will develop to ultimately
commercialize functional vascular conduits and grafts.
However, now more than ever, medical, regulatory, and
commercial considerations must be integrated into a trans-
lational strategy for one to succeed in delivering these ad-
vances to patients in a commercial product. Although most
will be first in class, they must deliver the same clinical ef-
fectiveness and commercial feasibility of any drug or device.
Also, heart and vascular disorders present a wide variety of
translational challenges from fundamental science and en-
gineering to practical aspects of production and delivery
and, in some cases, demonstration of comparative value over
more traditional alternatives. Added to that is the challenge
of developing business models that balance the cost of de-
velopment and future revenue potential.
Having previously examined the broad data on the
treatment opportunities in the cardiac and peripheral vas-
cular space,3 we now performed a more detailed analysis of
specific treatment opportunities to determine the strongest
opportunities for regenerative therapies as well as the clinical
and commercial challenges they may face. We analyzed the
therapeutic need and commercial opportunity with a de-
velopment perspective, the goal being to acquire, consoli-
date, and analyze data and information that could better
enable astute choices by those developing or hoping to de-
velop regenerative medicine therapies and devices in this
clinical space.
Methods
Estimate of opportunity analysis
Medical information about patients includes diagnoses
and procedures coded using the International Classification
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
codes. ICD-9-CM codes were reviewed down to a billable
code in both diagnosis and procedure categories and culled
of codes irrelevant to use of a regenerative therapy. Estimates
of incidence for the remaining ICD-9-CM codes were made
using the Center for Disease Control’s National Center for
Health Statistics database. Estimates of incidence were cap-
tured for first and second diagnoses and all diagnoses. The
National Hospital Discharge Survey (NHDS) is a national
probability survey designed to meet the need for information
on characteristics of inpatients discharged from non-Federal
short-stay hospitals in the United States. From 1988 to 2007,
the NHDS collected data from a sample of *270,000 inpa-
tient records acquired from a national sample of about 500
hospitals through 2006. Beginning in 2007, the sample size
was reduced to 239 hospitals; so, we used data collected
from 2004 to 2006 to give us a consistent, yet broad estimate
of the relative opportunity between indications.
The methods employed in the NHDS are covered in detail
in Dennison and Pokras.23 In brief, the survey uses a three-
stage probability design, including both manual and auto-
mated medical records. The stages are primary sampling
units (PSUs), hospitals with PSUs, and discharges within
hospitals, making sure that the largest PSUs and hospitals
are included. The target sample size is 250 discharges from
manual hospitals and 2000 discharges from automated sys-
tem hospitals. The sampling of hospitals is based on a na-
tional probability sample of discharges from noninstitutional
hospitals excluding government hospitals, located in all
states and the District of Columbia. Only hospitals with an
average length of stay of fewer than 30 days for all patients,
general hospitals, or children’s general hospitals are included
in the NHDS. The NHDS estimates are prioritized based on
national aggregation statistics, national trend statistics, and
aggregate statistics for the four main Census regions of the
U.S. SESUDAAN (a standard errors program for computing
standardized rates from sample survey data) and SUDAAN
(a program especially suited for survey data [RTI Interna-
tional]) are used to calculate variances. We recognize that we
may not capture all relevant clinical settings by using the
NHDS, but with 500 hospitals captured and the measures the
National Center for Health Statistics has put in place to ar-
rive at an accurate sampling, we feel that this is the best
source of consistent data. Since our main interest is in com-
paring data for various procedures, we feel that this ap-
proach is acceptable. Naturally, if NHDS introduced bias
during the down select, this would translate to some bias in
our analysis, but we believe that they would have carefully
avoided this at the time.
The design of the NHDS requires that the survey data be
inflated or weighted to produce national estimates. There are
three components to the final weight: inflation by reciprocals
of the probabilities of sample selection, adjustment for non-
response, and population weighting ratio adjustments. The
size of the treatment opportunity was calculated for years
2004–2006 using the SAS Ver. 9.2 statistical programming
package. The findings and conclusions derived from this
data are those of the authors and do not necessarily represent
the views of the Research Data Center, the National Center
for Health Statistics, or the Centers for Disease Control and
Prevention.
Analysis of the vascular access opportunity required
outpatient data. Outpatient data on the incidence and
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prevalence of vascular access were obtained from the Fistula
First Breakthrough Initiative, which is a network of vascular
access experts and stakeholders. The organization has col-
lected monthly data on vascular access procedures from a
network of thousands of outpatient facilities across the U.S.
since 2003. Monthly data from 2004 to 2010 on the incidence
and prevalence of vascular access procedures were used to
estimate the opportunity for this indication. The data were
downloaded in Microsoft Excel from the FistulaFirst.org
website.
Gap analysis
Gap analyses were performed using data collected
through PubMed literature search as well as Google internet
search. We relied on multiple reviews in areas, where a
broad assessment of practice or science was needed. Profes-
sional medical practice guidelines served as standards for
current state of the art, where available. Each gap analysis
(GAP) was done by indication by first defining the likely
patient population based on current medical practice. The
opportunities were then assessed based on treatment objec-
tives for current standing, present deficiencies, and remain-
ing or unfulfilled medical need.
Results
From both a technology and therapeutic target perspec-
tive, cardiovascular and peripheral vascular indications are
closely related. Several biological processes, such as inflam-
mation, vascularization, and regenerative signaling, inter-
sect24–27 among these disease contexts. For this reason, we
analyzed the therapeutic opportunities in cardiac and pe-
ripheral vascular medicine as a combined group referred to
as ‘‘cardio/vascular.’’ It was clear that there were two cate-
gories of technology opportunity within the cardio/vascular
disease space, (1) materials and grafts for vascular repair or
bypass and (2) regenerative therapies for revascularization or
regeneration. The first step was to understand the medical
need and treatment incidence in each target indication.
General prevalence
Statistics from the American Heart Association estimate
that over 81 million people in the U.S. have some form of
cardiovascular disease.1 The prevalence of coronary artery
disease is estimated as 17 million and there are*10.2 million
patients who suffer from angina. There are 8.5 million
myocardial infarcts and 5.8 million patients with heart fail-
ure. A surprising 650,000 individuals have some form of
congenital cardiovascular defect (Fig. 1).
U.S. prevalence of peripheral vascular disease is 5.7 mil-
lion for patients older than 40 years of age representing 4.5%
of the population (Table 1). This prevalence rises to 14.5% in
patients older than 70 years of age; therefore, the prevalence
of peripheral vascular disease might be expected to increase
with the current aging of the U.S. population.
The hospital discharge data from our database were used
to examine the cardiovascular therapeutic targets more clo-
sely, looking at treatment incidence in hospitalized patients
from 2004 to 2006. A top-level analysis comparing cardio-
vascular and peripheral vascular targets, as noted previ-
ously,3 indicated that the incidence of treatments for
cardiovascular disease heavily outweighed peripheral vas-
cular targets, accounting for 96% of the regenerative therapy
opportunity within the cardio/vascular space. Herein we
further dissected the opportunity to understand the inci-
dence of individual treatment targets within each major
category as they relate to the different types of regenerative
technologies.
Estimate of opportunity and GAP analyses
by medical indication
Detailed market evaluations are often performed by ana-
lysts and potential partners when evaluating a product in the
clinic; however, we contend that this information may also
be vital much earlier in the translational process and should
guide decisions from research goals to resource allocation
and be an integral part of a company’s early clinical strategy
and business model development.
FIG. 1. Prevalence of
cardiovascular disease in the U.S.
(2006). Prevalence is an estimate of
how many people have a disease at
a particular point in time. Data on
the prevalence of cardiovascular
disease in the U.S. was based on
2010 update of the Heart Disease
and Stroke Statistics of the
American Heart Association.1 The
data is based on the National
Health and Nutrition Examination
Survey and includes data collected
from 2003 to 2006 against 2006
census population estimates.
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Vascular repair
Patch grafts and vessel replacement. Patch graft an-
gioplasty is used to prevent stenosis and thrombosis at the
site of an arteriotomy, a cut or opening in the arterial wall. A
lesion that reduces the remaining arterial circumference is
major indication for a patch graft. Patch grafts are currently
fashioned from an autogenous vein, pericardium, or syn-
thetics. Vascular surgeons prefer autogenous vein patches for
small to medium caliber vessels, while synthetic material is
used for large caliber vessels like the aorta or iliac arteries.
Our estimate of opportunity analysis (EOA) analysis of patch
graft procedures estimated the incidence of tissue grafts and
synthetic grafts to be very similar (Fig. 2A). Clinically, there
seem to be only small differences in performance between
synthetic and vein grafts in carotid patch angioplasty.28 In
addition, vascular replacements, using the autogenous vein
for small-caliber applications and synthetics for large caliber
added another 15,000 procedures for repair of both small-
and large-caliber vessels 2005–2006 (Fig. 2B). This suggests
that there is a comparable need for both large- and medium-
to small-caliber vessels or conduits for vascular repair.
Endocardial repair. Biomaterials prostheses and conduits
are also used in endocardial repair, the largest and most
well-known application being valve replacement. Discussed
elsewhere,3 the EOA analysis suggests a large opportunity
for valve replacement of over 50,000 procedures per year
(Fig. 3A). Yet, as noted in the initial report in this series,3 the
opportunity for a substantially novel tissue valve is likely to
be limited in the adult due to the clinical performance of
current tissue valve alternatives. However, in pediatric ap-
plications, long-term function and growth of valve leaflets
would be a distinct advantage over present alternatives.29
Tissue grafts used for partial repair or replacement num-
bered close to 70,000 by 2006 (Fig. 3B).
Additional endocardial applications, many to treat con-
genital defects, had a combined incidence of over 40,000 in
2006 (Fig. 3C). The use of prosthetics appears to be nearly
equal to the use of tissue grafts; although the type of material
is unspecified in a large number of reported septal and en-
docardial repairs.
Aortic aneurysm. EOA: The World Health Organization
statistical data calculate death from aortic aneurysms in the
Table 1. United States Prevalence of Peripheral
Vascular Disease
U.S. demographic—2009 Prevalencea
‡ 40 years of age,
ABI < 0.90
4.5% (95% CI 3.1%–5.3%)
‡ 70 years of age,
ABI < 0.90
14.5% (95% CI 10.8%–18.2%)
U.S. demographic—2009 Populationb Approximate PAD
prevalence
(in millions)
‡ 40 years of age 73,858,958 3.3M (95% CI 2.3–4.1)
‡ 70 years of age 16,473,874 2.4M (95% CI 1.8–3.0)
aData: Selvin and Erlinger (2004).59
bData: Annual estimates of the resident population by sex and
five-year age groups for the United States: April 1, 2000 to July 1,
2009 (NC-EST2009-01) U.S. Census Bureau Population Division,
Release Date, June 2010.
ABI, ankle brachial index (The ratio of blood pressure in the lower
leg over blood pressure in the arm); CI, confidence interval; PAD,
peripheral vascular (arterial) disease.
FIG. 2. The incidence of vascular repair. The
graphs show the incidence of vascular repair
in U.S. short-term stay discharged patients.
(A) The incidence of patch grafts. (B) The
difference in incidence of large- versus small-
caliber vessel replacement procedures. Data
are based on listed procedures upon discharge
as reported in the U.S. National Hospital
Discharge Survey data 2003–2006.
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U.S. to be just over 53 per 1 million people accounting for
over 15,000 deaths.30 AAA account for 9000 of these deaths.
The EOA data estimate that aortic aneurysms without rup-
ture represent a possible regenerative treatment target
numbering *50,000 discharges per year based on primary
and secondary diagnoses (Fig. 4A). In spite of the potential
market, the repair of aortic aneurysms had undergone
drastic transitions toward an endovascular repair that use a
covered stent, these numbered just over 23,000 by 2006 (Fig.
4B). There is a large difference between the incidence and
repair of aortic aneurysms. This is largely due to the
threshold for repair when the benefit exceeds the risk of the
aneurysm repair. For this reason, most patients are observed
until the aneurysm attains a size of 5.5 cm, when rupture risk
gains significance.
Of importance, repair of AAA less than 5.5 cm in diameter
has not led to improvements in mortality compared to a
waiting surveillance program.31
GAP: Currently, the most advanced technology for repair
is a minimally invasive procedure using an endovascular
stent graft that is composed of a deployed stent with a
polytetrafluoroethylene (PTFE) or Dacron lining introduced
through the femoral artery (e.g., Medtronic AneuRx, or
Gore). Endovascular procedures for AAA intervention offer
several near-term advantages, such as lower operative mor-
tality (1.8% vs. 4.3%), shorter hospital stays, and decreased
short-term patient morbidity. However, a large randomized
trial conducted in the United Kingdom compared open versus
endovascular repair and found no long-term differences in
total and aneurysm-related mortality.2 Endovascular repair
resulted in three to four times higher rates of graft-related
complications and re-interventions compared to open repair
even after 4 years. This translated to a higher overall cost
associatedwith use of the endovascular prosthesis with amean
cost of aneurysm-related admissions totaling over $4,568 more
(total costs $23,153 compared to $18,586) during an 8-year
follow-up period with costs of primary and later graft-related
admissions contributing almost equally to this difference.
A systematic review by Jonk et al. concluded that endovascular
repair of AAA was not cost-effective regardless of the health
status of the patient.32 This suggests that next-generation
prosthesis should be endovascular and ideally reduce the
incidence of complications and re-intervention over time.
Apart from simply competing as an alternative conduit,
what could a regenerative alternative offer over PTFE and
Dacron? Because a biological graft would remodel, better
integration of aorta and graft might be a possibility, but gi-
ven the older target patient population, it also means that
reliance on tissue remodeling in this patient population may
be challenging, and the durability compared to synthetics
may be questioned. Because most complications involve the
patient anatomy (proximity to vessels of the bowel and
kidneys, for example), a biological graft would not offer an
advantage over synthetics with respect to prevention of
complications or degeneration of the adjacent aorta. Since
reoperation is fraught with high risk, safety, reliability, and
durability would be paramount. For these reasons, we
conclude that in aortic aneurysm repair, there is no promi-
nent medical need that a regenerative implant could rea-
sonably address and although a theoretical target for
regenerative therapy, it is unlikely to be a feasible medical or
commercial target.
Vascular access. EOA: Vascular access is a means of
achieving a high-volume blood flow for the purpose of he-
modialysis in patients with renal failure. This high flow
needs to be easily accessed by a dialysis nurse with a needle
stick, provide high flow to operate the dialysis unit, and yet,
minimize infection risk. While a long-term catheter provides
a degree of convenience, these devices are plagued by risks
FIG. 3. Incidence of endocardial
disorders and procedures. (A)
Incidence of valve disorders versus
replacements. (B) Incidence of
tissue grafts versus replacement
with mechanical heart valves. (C)
Incidence of other endocardial
repair procedures.
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of infection, occlusion, and long-term damage to vessels
within the chest. For this reason, catheters are actively dis-
couraged in favor of surgical vascular access. The gold
standard for surgical vascular access is an arteriovenous
(AV) fistula created with connection of an artery and a vein.
AV fistula procedures and associated repairs represented
only 14% of the large hospitalized hemodialysis patient
population between 2004 and 2006 (data not shown). The
majority of the vascular access procedures are performed
on an outpatient basis. For this reason, the analysis was
FIG. 4. Aortic aneurysm diagnoses
and procedures. Aortic aneurysm
repair is an opportunity for device
intervention, but a traditional
medical device employing a
biomaterial is likely to remain the
method of choice. (A) The incidence
of hospitalized patients with
nonruptured aortic aneurysm. (B)
The incidence of aortic grafts versus
aneurysm repair in other vessels.
FIG. 5. Prevalence and
incidence of U.S. vascular
access procedures. Data on
vascular access procedures
were obtained from Fistula
First.org,14 which tracks
vascular access procedures
from a large U.S. network of
institutions on a monthly
basis. (A) The percent
prevalence of the different
long-term vascular access
procedures. (B) The 7-year
trends in incidence between
long-term vascular access
procedures.
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performed using data tracked from a large network of U.S.
institutions and reported on a monthly basis by Fistula-
First.org.33 While there is a high incidence of venous cathe-
terization (not shown), catheterization extending to 90 days
and beyond is discouraged and infrequent (Fig. 5A) and
patients with chronic kidney disease will require vascular
access beyond catheterization. The creation of an AV fistula
is the first medical choice.34,35 AV fistulas are the preferred
methods of hemodialysis access mandated by the Centers for
Medicare and Medicaid services34 and recommended by the
KDOQI36 guidelines for care of the dialysis patient. Despite
these guidelines, a large number of patients do not have
adequate vein for successful creation of a mature fistula
necessary for hemodialysis. An appropriately designed bio-
logic alternative may reduce the complications associated
with prosthetic grafts currently used when adequate vein is
not available.
While the use of AV fistulas is steadily increasing, the
creation of fistulas at nearly twice that frequency highlights
the failure of many fistulas to reach a state where they can be
used clinically (Fig. 5B). There is a smaller, but persistent use
of AV grafts (Fig. 5). The changes in prevalence year-to-year
between AV fistulas and grafts appear to mirror each other
suggesting that AV grafts and AV fistulas continue to com-
pete in a certain segment of the patient population (Fig. 5A).
The data suggests that there is an opportunity for a regen-
erative alternative both in the current AV fistula population
and would otherwise receive an AV graft.
While peripheral bypass grafting is attractive from a
market standpoint, the complications from potential graft
failure are substantial and the margin to exceed performance
of currently used autogenous vein is narrow. In contrast, an
AV fistula presents advantages both from a production
standpoint as the graft lengths are shorter, but also may
present less immediate complications to the patient in the
event of graft failure.
Our EOA and gap analyses suggest that a biological con-
duit or graft would compete with expanded PTFE (ePTFE) in
an initial patient population of just over 50,000 individuals per
year if one includes revisions and replacements.
GAP: Currently, when adequate vein is not available, the
need for AV grafts is met with synthetic grafts like ePTFE
(normally 6–8mm in diameter) or the lesser used biological
alternative, which is, processed bovine conduits. Both ePTFE
and bovine grafts have high short-term patency rates even
though endothelialization extends only 1–2 cm beyond the
anastomoses and there is little transluminal endothelializa-
tion observed in humans.37 This feature may explain, in part,
the poor long-term patency of ePTFE and bovine grafts. Both
grafts suffer from structural integrity issues, PTFE develops
mechanical failure with development of pseudoaneurysm at
sites of repeated puncture, while biologic grafts have been
noted with frequent formation of aneurysm formation. PTFE
also carries lifelong risks for infection, a feature that is far less
common among biologic alternatives, such as vein. Profes-
sional and hospital services are estimated at $11,477 for AV
graft surgery38 and a total of $20,792 for all inpatient ser-
vices.39 In 2006, yearly patient costs were $71,616 for patients
with grafts versus $59,347 for AV fistulas. Hemodialysis
access costs were highest for grafts at $7,377 compared to
only $3,284 for AV fistulas. In summary, prosthetic AV graft
materials carry a higher complication rate and annual cost
compared to vein; thus, for patients in whom vein is not
available, there is a niche for regenerative conduits that may
overcome some of these obstacles. A problem common to all
forms of dialysis access is the development of scar tissue at
the junction with the host vessel, known as intimal hyper-
plasia. The compliance mismatch of PTFE, in particular, is
believed to accelerate this process. This disease is so prob-
lematic, in fact, that an average vascular access has an av-
erage longevity of under 18 months, obligating many of
these patients to repeat procedures.
These features suggest that a superior engineered graft
will be one that can seamlessly integrate with the host vessels
permitting repair, while limiting the hyperplastic reaction at
the anastomoses. An ideal engineered graft would also be
one with a more favorable compliance mismatch than cur-
rently available prosthetic grafts. It will also maintain a du-
rable artery-like vessel that can endure repeated access
without primary wall degeneration. It is conceivable that
physical or pharmacologic design features may someday
limit the intimal hyperplasia. The lengths needed for vas-
cular access range from ‡ 20 to 40 cm; therefore, production
issues for vascular access become more manageable than for
long peripheral artery bypass grafts. It should be noted that
current hemodialysis access costs for a graft is currently
under $8,000. The GAP for vascular access is summarized in
Table 2.
Peripheral vascular disease
Surgical intervention. EOA: Peripheral vascular (arterial)
disease (PAD) is due to atherosclerosis of the peripheral
vessels. While several biologics and stem cell therapies have
been advocated to stimulate a more robust microvascular
network, these are unlikely to achieve clinical goals of limb
salvage when macrovascular disease is present. In those in-
stances, a long peripheral bypass will still be required. There
are two primary categories of arterial insufficiency that merit
discussion as they have an impact on clinical need for re-
generative products. Patients with mild to moderate arterial
insufficiency who have pain after walking certain distances
carry a diagnosis of claudication. The mainstay of therapy
includes lifestyle modification, such as smoking cessation
and an exercise program. With this approach, most patients
achieve their lifestyle goals without any intervention. In fact,
the risk of amputation among these patients is quite low,
under 5% at 5 years. It is for this reason that the perioperative
risk (myocardial infarction, graft failure, infection, and
wound complications) has widely discouraged invasive in-
tervention among these patients. It remains unlikely that
these patients will represent a meaningful population for
engineered grafts, although biologic and stem cell therapies
potentially would have a more favorable risk to benefit
profile in this population. In contrast, patients with critical
limb ischemia (CLI) have a far more advanced, often multi-
level, arterial disease. These patients have rest pain symp-
toms that are constant and unremitting or may have
nonhealing wounds or gangrene. The risk of limb loss is high
among these patients. The long length of vein necessary for
bypass and the likelihood that these patients may have had a
previous harvest of vein for a cardiac bypass or bypass of the
other lower extremity is high. The use of prosthetic bypass
grafts for long leg bypass has dismal outcomes and for these
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reasons, patients with CLI represent a broad niche for an
engineered bypass.
Importantly, not all CLI patients are candidates for bypass
due to unavailability of outflow in the form of small vessels
in the foot required to keep a bypass open. Therapies
that would increase microvascularization of the tissue are
considered to have theoretical potential for this patient
population.40 While endovascular options may present an
alternative for many patients with PAD, there continues to
be an ongoing need for open bypass due to superior dura-
bility and utility for extensive disease compared to most
endovascular options.
Hospitalizations with a diagnosis of PAD with gangrene
numbered nearly 50,000 patients per year suggesting that a
significant medical need exists for more aggressive inter-
vention to limit progression of CLI to this stage. The au-
togenous saphenous vein is the gold standard for peripheral
bypass; however, about 30% of patients needing a below the
knee revascularization procedure have inadequate saphe-
nous vein for grafting. This number increases to 50% for
those undergoing secondary procedures,40 a population,
where an engineered biological graft would be especially
valuable. CLI symptoms of rest pain, ulceration, and gan-
grene combined for a total of up to 83,000 primary and
secondary diagnoses in a single year (Fig. 6A). Of those, two-
thirds or just over 55,000 CLI patients may be candidates for
vascular surgery and nearly 28,000 nonsurgical candidates
might be helped by cell therapy. Peripheral vascular grafts
and bypass grafts numbered from over 66,000 in 2004 to just
over 54,000 in 2006 confirming our estimates based on di-
agnosis (Fig. 6B). The decrease in grafts and bypass grafts
from 2004 to 2006 were offset by an increase in the use of
peripheral artery stents. PAD represents a substantial op-
portunity for both cell-based regeneration of the microvas-
culature and vascular grafting in different, but overlapping
patient populations. The autogenous saphenous vein is the
current gold standard in peripheral bypass grafting although
there is opportunity for a regenerative graft to improve on
saphenous vein in availability, reduced morbidity, and im-
portantly, toward limiting intimal hyperplasia, one of the
most troublesome causes of failure among vascular bypasses.
GAP: Synthetic grafts are used in CLI when there is no
alternative option, including other autogenous vessels. First
generation PTFE grafts had inferior long-term patency com-
pared to the saphenous vein, particularly below the knee;37
new heparin-bonded prosthetic grafts are debatable with re-
gard to improved patency, if any. We conclude from the GAP
that a biological bypass graft should ideally narrow that
performance gap in below the knee procedures. It would
ideally be off-the-shelf as patients with CLI have the highest
risk of amputation, and delay in prompt treatment can rapidly
lead to infection, gangrene, and limb loss. Market penetration
will also be challenged by increased use of endovascular
procedures and improvements in the drug-eluting stent and
balloon technologies,41 although the use of such stents is
limited and relatively undefined in many cases of CLI. The
GAP for a peripheral bypass graft is summarized in Table 3.
Therapeutic angiogenesis. GAP: Cell therapies for tissue
ischemia can act in two ways: (1) through proangiogenic
signaling that acts in a paracrine manner to promote or
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directly contributing to the advance and/or stabilization of
the microvascular network through the addition of endo-
thelial cell precursors or supporting pericytes, for example.
Angiogenesis is essentially regeneration of the microvascu-
lature.
A growth factor or cell-based therapy could, in theory,
increase the microvascular network and collateral circula-
tion. Such technologies may have greatest utility in some
chronic wounds, where the macrovascular system is func-
tional, but the local microvascular supply may be impaired.
In the context of claudication, symptoms of intermittent
pain without ulcers or gangrene, lifestyle modification,
such as exercise and smoking cessation will remain cen-
terpieces of treatment. While bypass carries a higher risk to
benefit profile and is considered inappropriate for the vast
majority of claudication patients, injected or cell-based
therapy may offer symptom relief, while presenting mini-
mal risk to the patient. In the treatment of CLI, the critical
nature of the disease and the lack of surgical options for a
third or more of the patient population create a greater need
for a regenerative therapy to augment nonsurgical options.
A cell therapy will likely be used in conjunction with
therapies, such as bypass rather than as an alternative in
CLI. The GAP for regenerative therapy for PAD is sum-
marized in Table 3.
Cardiovascular
EOA: Coronary artery bypass is the first indication that
comes to mind for vascular grafting. AMI, for which coro-
nary bypass grafts (CABG) is primarily used for, had a high
initial incidence of 684,000–743,000 discharges from 2004 to
2006 based on primary and secondary diagnoses (Fig. 7A).
Looking at the type of procedures used to treat AMI, CABG
still outnumbered the use of stents between 2004 and 2006
reaching a high of ‡ 823,278 grafts in 2005* (Fig. 7B). Of
particular interest to regenerative medicine, is the incidence
of recurrent atherosclerosis in the CABG, which could ne-
cessitate regrafting (Fig. 7C). It is estimated that 33% of pa-
tients undergoing coronary bypass will require one or more
regrafts.42 The incidence of coronary atherosclerosis of au-
togenous veins outweighed the incidence of atherosclerosis
in artery bypass grafts. How much of this is due to the
predominant use of autogenous vein in CABG was not dis-
cernable from the EOA data. However, the incidence data
mirror clinical findings that 10-year patency rates for sa-
phenous vein grafts are 61% versus 85% for internal mam-
mary artery grafts,43 although not all artery grafts may
perform equally well. A recent clinical study found no dif-
ference in patency rates between saphenous vein grafts and
radial artery grafts harvested from the arm at 1 year with the
radial artery grafts having a higher associated morbidity and
cost of harvest.44
GAP: AMI is the second most prevalent cardiovascular
disorder after congestive heart failure (Fig. 8). Four hundred
forty-eight thousand inpatient bypass procedures were per-
formed in 2006.1 Using data from the EOA analysis, it was
clear that treatment of acute AMI has a high success rate (Fig.
9) with 97% of all hospitalized cardiovascular disease pa-
tients discharged alive, 70% to home. Pooled Framingham
Heart Study, Atherosclerosis Risk in Communities Study,
and Cardiovascular Health Study data from the National
FIG. 6. Dissection of the cardiac
bypass medical need and
opportunity. (A) The incidence of
acute myocardial infarction and
subsequent symptomatic need for
readmission. (B) The incidence of
coronary bypass grafts (CABG)
versus endovascular stents. (C) The
incidence of atherosclerosis in
different types of CABG.
*CABG procedures involving more than four bypass grafts are
coded the same as quadruple bypass.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Heart, Lung and Blood Institute estimate that within 5 years
after first myocardial infarction, 33% of men and 43% of
women ‡ 40 years of age will die, 16% of men and 22% of
women aged 40–69 will suffer a recurrent myocardial in-
farction or fatal coronary heart disease, and 7% of men and
12% of women will develop heart failure within 5 years.1 The
incidence of atherosclerosis in a bypass graft was *51,000
per year between 2004 and 2006 (Fig. 7). By excluding pa-
tients treated with bypass, we calculate that *150,000 AMI
patients (25% of AMI patients) were treated with stents ra-
ther than bypass. Assuming that the frequency of en-
dovascular intervention will be similar to interventions for
the initial AMI, this leaves 38,250 of patients with athero-
sclerosis of their bypass grafts as candidates for re-graft. As
stents continue to improve, this proportion may decrease
further. A review of the literature reveals that autogenous
arteries and veins will still be the first choice for re-graft
whenever possible and that autogenous vessels can be har-
vested even for patients undergoing their third CABG pro-
cedure,42 likely due to the short length needed for these
FIG. 7. The medical need in
peripheral artery disease. (A)
Three-year U.S. hospital discharge
data based on first and second
listed diagnoses related to various
stages of peripheral artery disease.
(B) The comparative use of vascular
shunts or bypass grafts versus
stents during the 3-year period.
FIG. 8. The medical need in
cardiovascular disease (all
diagnoses vs. primary and
secondary diagnoses).
Comparison of primary and
secondary reported incidence
versus all reporting
estimates, both the current
and unmet need in
hospitalized patients with
cardiovascular disorders over
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procedures. Given the track record of bypass procedures and
the morbidity associated with vessel harvest, the barrier to
adoption of an engineered vessel is likely to still be high.
Unlike CLI, failure of a CABG graft can have immediate life-
threatening impact45 and the extensive experience with suc-
cessful CABG grafting43 will make it hard to justify the use of
an alternative unless absolutely necessary. Furthermore, the
patient population who may need engineered conduit al-
ternatives will be limited to a percentage of regraft patients
lacking available autogenous artery and vein options. Over
time, advantages in lower patient morbidity from avoiding
vessel harvest will be an advantage, but we believe it is
unlikely to be a key driver in the decision to use an autog-
enous alternative without substantial long-term data and
clinical experience. Supporting data could come from use of
a regenerative graft in peripheral bypass contexts, although
there remain key differences in the requirements of and
techniques used by peripheral vascular and cardiac sur-
geons. For these reasons, while the market is potentially
large, there may be several initial barriers to adoption of
engineered alternatives to CABG. The comparison of the
vascular graft opportunities with findings of the GAP fac-
tored in is summarized in Table 4.
Heart failure. EOA: The data suggest that current man-
agement does well in saving the lives of patients with AMI
due to ischemia, but the longer term impact of cardiac
damage appears to be another matter. Heart failure is the
largest opportunity within the cardio/vascular space (Fig. 8).
Of the cardiac patients discharged to long-term care, 65% of
them have heart failure (Fig. 9). Since heart failure is simply
managed medically for many patients, we compared pri-
mary and secondary diagnoses to all listed diagnoses to get a
sense of how many individuals hospitalized each year had
heart failure. EOA analysis comparing primary and sec-
ondary diagnoses versus all diagnoses revealed that a large
number of heart failure patients are hospitalized each year
(Fig. 8). Early-stage treatment post AMI represents a popula-
tion of about 70,000 to just over 80,000 hospitalized patients
per year. In comparison, diagnoses of congestive heart failure
reach*2 million discharges based on primary and secondary
diagnoses and expand to nearly 4 million patients if one takes
into account all hospitalized patients with a diagnosis of
congestive heart failure (Fig. 8). It is clear from the incidence
data that early regenerative treatments to improve cardiac
perfusion and/or function should ideally tackle the primary
unmet medical need by intervening to limit the progression to
heart failure and/or by restoring cardiac function.
Cardiac ischemia. GAP: It is reasonable to anticipate that
treatment of microvascular cardiac ischemia will be mecha-
nistically similar to the treatment of PAD. A cell therapy
might be introduced in a transvascular procedure, injection
into the circulation or injection into the myocardium at the
time of a cardiac catheterization or endovascular procedure
to treat angina symptoms. Post AMI, cell therapy may be
introduced into the site of infarct to promote optimal healing
of the cardiac wall. Animal and human studies to date
suggest that cell therapy can exert a positive effect on left
ventricular function and limit the extent of scarring although
reviews of the clinical data to date46–49 have confirmed that
the results are variable and improvements modest though
the procedures are safe. Other procedures exist and, for ex-
ample, treatment to promote transmyocardial and other re-
vascularization procedures approached 5000 procedures in
2006.3 Of note is that while medical therapy can reduce the
risk of heart failure in asymptomatic patients with left ven-
tricular dysfunction, only a small difference is observed in
mortality between patients managed in a preventative versus
a therapeutic approach for heart failure.50 For these reasons,
more aggressive interventions may be warranted.
The majority of clinical studies to date have examined the
infusion of bone marrow stem cells into the heart as an ap-
proach to restoring lost function. The durability of the dif-
ferences in healing and function is unclear and the
mechanism of action is also unclear51 although promotion of
angiogenesis, limiting inflammation, and promoting the re-
generative phase are all possibilities. Further evidence of the
mechanism of action for these therapies is still needed. The
GAP for regenerative therapy for cardiac ischemia is sum-
marized in Table 4.
Cardiomyopathy. GAP: AMI is not the only cause of heart
failure and, in fact, can be caused by viral infection, hyper-
tension, valve dysfunction, and renal failure.52 Similar to the
use of cell therapy to improve microvascularization, the pri-
mary gap at present is in determining and optimizing the
mechanismof action anddelivery approach for these therapies.
Defining cell sourcing and integration of injected cells into
cardiac tissues will be other considerations. The GAP for re-
generative therapy to reverse heart failure is summarized in
Table 5. An effective therapy for heart failure is a clear medical
need with limited alternative treatments.53,54 Currently, a
multi-disciplinary approach to management of heart failure
FIG. 9. Medical need in cardiovascular disease discharge
status in all cardiac disease. (A) Discharge status shows that
most cardiovascular patients are discharged alive, to the
home. (B) Heart failure is the principle disorder in patients
discharged to long term care facilities. STC, short term care;
LTC, long term care.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































appears to be most effective.53,55–57 Early intervention may
present advantages by prevention of clinical heart failure, both
to the patient and the resources of the medical system in gen-
eral. Again, much work remains to define the best cells or
factors to achieve this goal. To date, the absence of scientific
data on mechanism(s) of action is still a significant gap stand-
ing in the way of a regenerative therapy to halt progression to
heart failure.49,58 Cells fromdifferent sourcemay not be equally
effective at all stages,25 the same will be true for regenerative
factors. Although these therapies remain in their infancy, the
market size and medical need justify the continued effort and
investment. It seems inevitable at this point that regenerative
products will become as important to cardiac patients as cur-
rently used angioplasty, medical therapy, and surgery.
Summary
Although generalized projections may identify high-yield
areas for clinical products, more detailed information of the
potential barriers to clinical adoption of new technologies is
necessary. The results of our analysis dispel some long-held
assumptions regarding paths to the marketplace and confirm
the translational importance of performing a GAP that in-
corporates a realistic EOA for each application of a technol-
ogy. To summarize our findings:
(1) The opportunity for biological patch grafts and vessel
replacements is modest at around 15,000 procedures
per year. The gap in medical need is small compared to
other cardio/vascular indications.
(2) AAA repair represents *20,000 procedures per year.
However, the long track record of current technologies
and competing endovascular technologies make this
area an unlikely commercial target for regenerative
technologies.
(3) Vascular access offers one of the best opportunities for a
tissue-engineered vascular graft. At minimum, such a
graft would serve as an alternative to current AV grafts
(over 30,000 per year), if a regenerative conduit could
compete competitively with the current gold standard
of autogenous vein (also around 30,000 per year).
(4) Extensive surgical experience make CABG a difficult
indication of a tissue- engineered vascular graft. Despite
a large initial CABG population, regraft procedures will
likely face increasing competition from endovascular
innovations in a patient population of just over 30,000
per year. The CABG indication will likely require sup-
porting data from other vascular indications to be ap-
proachable clinically and commercially.
(5) PAD (nonaortic) represents over 60,000 procedures per
year now treated using a graft, bypass, or en-
dovascular procedures. PAD patients with intermittent
claudication (over 35,000 in 2006) represent an op-
portunity for cellular therapy, but not likely surgical
grafts. Critical limb ischemia (CLI) represented over
90,000 primary and secondary diagnoses. Subpopula-
tions of CLI patients are candidates for both cellular
therapy and vascular bypass grafting. An engineered
vascular graft could offer several clinical benefits over
native vessels in availability, consistency, reduced
morbidity, and extent of intimal hyperplasia. Ad-
vances in endovascular approaches to PAD will reduce
some of the potential in the area, but is unlikely to
completely replace open surgical bypass among pa-
tient with extensive disease.
(6) Heart failure is the single largest treatment opportu-
nity for regenerative medicine at *2 million dis-
charges based on primary and secondary diagnoses
and close to 4 million patients if one includes all pa-
tients hospitalized with a diagnosis of congestive heart
failure. Cellular or biological therapy to treat ischemic
heart disease should ideally impact the progression to
heart failure and yield results superior to current
standards of care.
We believe that this information will help guide new re-
generative technologies to the areas of greatest clinical need.
Disclosure Statement
No competing financial interests exist.
References
1. Lloyd-Jones, D., Adams, R.J., Brown, T.M., Carnethon, M.,
Dai, S., De Simone, G., et al. Heart disease and stroke sta-
tistics—2010 update: a report from the American Heart As-
sociation. Circulation 121, e46, 2010.
2. Greenhalgh, R.M., Brown, L.C., Powell, J.T., Thompson,
S.G., Epstein, D., and Sculpher, M.J. Endovascular versus
open repair of abdominal aortic aneurysm. N Engl J Med
362, 1863, 2010.
3. Parenteau, N., Hardin-Young, J., Shannon, W., Cantini, P.,
and Russell, A. Meeting the need for regenerative therapies:
target-based incidence and its relationship to US spending,
productivity and innovation. Tissue Eng Part B Rev 18,
139, 2012.
4. Dahl, S.L., Kypson, A.P., Lawson, J.H., Blum, J.L., Strader,
J.T., Li, Y., et al. Readily available tissue-engineered vascular
grafts. Sci Transl Med 3, 68ra9, 2011.
5. Weinberg, C.B., and Bell, E. A blood vessel model con-
structed from collagen and cultured vascular cells. Science
231, 397, 1986.
6. Niklason, L.E., Gao, J., Abbott, W.M., Hirschi, K.K., Houser,
S., Marini, R., et al. Functional arteries grown in vitro. Science
284, 489, 1999.
7. Ratcliffe, A. Tissue engineering of vascular grafts. Matrix
Biol 19, 353, 2000.
8. L’Heureux, N., Germain, L., Labbe, R., and Auger, F.A.
In vitro construction of a human blood vessel from cultured
vascular cells: a morphologic study. J Vasc Surg 17, 499, 1993.
9. Laflamme, K., Roberge, C.J., Pouliot, S., D’Orleans-Juste, P.,
Auger, F.A., and Germain, L. Tissue-engineered human
vascular media produced in vitro by the self-assembly ap-
proach present functional properties similar to those of their
native blood vessels. Tissue Eng 12, 2275, 2006.
10. Badylak, S.F., Lantz, G.C., Coffey, A., and Geddes, L.A.
Small intestinal submucosa as a large diameter vascular
graft in the dog. J Surg Res 47, 74, 1989.
11. Lantz, G.C., Badylak, S.F., Hiles, M.C., Coffey, A.C., Geddes,
L.A., Kokini, K., et al. Small intestinal submucosa as a vas-
cular graft: a review. J Invest Surg 6, 297, 1993.
12. Shin’oka, T., Imai, Y., and Ikada, Y. Transplantation of a tissue-
engineered pulmonary artery. N Engl J Med 344, 532, 2001.
13. Hibino, N., McGillicuddy, E., Matsumura, G., Ichihara, Y.,
Naito, Y., Breuer, C., et al. Late-term results of tissue-
engineered vascular grafts in humans. J Thorac Cardiovasc
Surg 139, 431, 2010.
MEETING THE NEED FOR REGENERATIVE THERAPIES 113
14. Ravi, S., and Chaikof, E.L. Biomaterials for vascular tissue
engineering. Regen Med 5, 107, 2010.
15. Critser, P.J., Voytik-Harbin, S.L., and Yoder, M.C. Isolating
and defining cells to engineer human blood vessels. Cell
Prolif 44 Suppl 1, 15, 2011.
16. Guillemette, M.D., Gauvin, R., Perron, C., Labbe, R., Ger-
main, L., and Auger, F.A. Tissue-engineered vascular ad-
ventitia with vasa vasorum improves graft integration and
vascularization through inosculation. Tissue Eng Part A 16,
2617, 2010.
17. Prichard, H.L., Manson, R.J., DiBernardo, L., Niklason, L.E.,
Lawson, J.H., and Dahl, S.L. An early study on the mecha-
nisms that allow tissue-engineered vascular grafts to resist
intimal hyperplasia. J Cardiovasc Transl Res 4, 674, 2011.
18. Duncan, D.R., and Breuer, C.K. Challenges in translating
vascular tissue engineering to the pediatric clinic. Vasc Cell
3, 23, 2011.
19. Gauvin, R., Ahsan, T., Larouche, D., Levesque, P., Dube, J.,
Auger, F.A., et al. A novel single-step self-assembly ap-
proach for the fabrication of tissue-engineered vascular
constructs. Tissue Eng Part A 16, 1737, 2010.
20. Norotte, C., Marga, F.S., Niklason, L.E., and Forgacs, G.
Scaffold-free vascular tissue engineering using bioprinting.
Biomaterials 30, 5910, 2009.
21. McAllister, T., Wystrychowski, W., Radochonski, S., Cierpka,
L. Dusserre, N., Zagalski, K., Garrido, S., and L’Heureux, N.
First Human Use of an Allogeneic Tissue Engineered Vas-
cular Graft. Dallas, TX: American Heart Association, 2011.
22. McAllister, T.N., Maruszewski, M., Garrido, S.A., Wy-
strychowski, W., Dusserre, N., Marini, A., et al. Effectiveness
of haemodialysis access with an autologous tissue-
engineered vascular graft: a multicentre cohort study. Lancet
373, 1440, 2009.
23. Dennison, C., and Pokras, R. Design and Operation of the
National Hospital Discharge Survey: 1988 Redesign. Vital
and Health Statistics Ser 1, Programs and Collection Proce-
dures, Center for Disease Control and Prevention, National
Center for Health Statistics, Atlanta, GA, 2000.
24. Davis, M.E., Hsieh, P.C., Grodzinsky, A.J., and Lee, R.T.
Custom design of the cardiac microenvironment with bio-
materials. Circ Res 97, 8, 2005.
25. Boudoulas, K.D., and Hatzopoulos, A.K. Cardiac repair and
regeneration: the Rubik’s cube of cell therapy for heart dis-
ease. Dis Model Mech 2, 344, 2009.
26. Dobaczewski, M., and Frangogiannis, N.G. Chemokines and
cardiac fibrosis. Front Biosci (Schol Ed) 1, 391, 2009.
27. Misra, A., and Mann, D.L. Treatment of heart failure beyond
practice guidelines. Role of cardiac remodeling. Circ J 72
Suppl A, A1, 2008.
28. Rerkasem, K., and Rothwell, P.M. Patches of different types
for carotid patch angioplasty. Cochrane Database Syst Rev
CD000071, 2010.
29. Yacoub, M.H., and Takkenberg, J.J. Will heart valve tissue
engineering change the world? Nat Clin Pract Cardiovasc
Med 2, 60, 2005.
30. NationMaster WHOSISv. Mortality Statistics - Aortic An-
eurysm and Dissection (Most Recent) by Country, World
Health Organization Statistical Information System via
NationMaster.com, Woolrich, NSW, Australia, 2010.
31. Lederle, F.A., Kane, R.L., MacDonald, R., and Wilt, T.J.
Systematic review: repair of unruptured abdominal aortic
aneurysm. Ann Intern Med 146, 735, 2007.
32. Jonk, Y.C., Kane, R.L., Lederle, F.A., MacDonald, R., Cut-
ting, A.H., and Wilt, T.J. Cost-effectiveness of abdominal
aortic aneurysm repair: a systematic review. Int J Technol
Assess Health Care 23, 205, 2007.
33. Spergel, L.M. July 2003–July 2011 AVF, AVG, and CVC
Data. Fistula First Data. Lake Success, NY: Fistula First,
2011.
34. Roy-Chaudhury, P. Hemodialysis Vascular Access
Dysfunction–Opportunities for Targeting an Unmet Medical
Need. End-Stage Renal Disease–Vascular Access, London,
UK: Touch Briefings, 2007.
35. Vascular Access Society. Guidelines. Vascular Access
Society, Lexungton, KY 2011.
36. KDOQI. NKF-KDOQI Clinical Practice Guidelines for Vas-
cular Access: Update 2000. In: Foundation, N.K., ed. NKF-
KDOQI Clinical Practice Guidelines, 2000.
37. Wilson, S.E. Biologic Response to Prosthetic Dialysis Grafts.
Vascular Access: Principles and Practice. 5th ed. Philadel-
phia, PA: Lippincott Williams & Wilkins, 2010.
38. Healthcare Blue Book. Arteriovenous Shunt. Brentwood,
TN: CareOperative LLC, 2011.
39. USRDS. Costs of End-Stage Renal Disease. Atlas-ESRDS:
United States Renal Disease System, 2010.
40. Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., Bakal, C.W.,
Creager, M.A., Halperin, J.L., et al. ACC/AHA 2005 Prac-
tice guidelines for the management of patients with pe-
ripheral arterial disease (lower extremity, renal, mesenteric,
and abdominal aortic): a collaborative report from the
American Association for Vascular Surgery/Society for
Vascular Surgery, Society for Cardiovascular Angiography
and Interventions, Society for Vascular Medicine and
Biology, Society of Interventional Radiology, and the
ACC/AHA Task Force on Practice Guidelines (Writing
committee to develop guidelines for the management of
patients with peripheral arterial disease): endorsed by the
American Association of Cardiovascular and Pulmonary
Rehabilitation; National Heart, Lung, and Blood Institute;
Society for Vascular Nursing; TransAtlantic Inter-Society
Consensus; and Vascular Disease Foundation. Circulation
113, e463, 2006.
41. Siablis, D., Kraniotis, P., Karnabatidis, D., Kagadis, G.C.,
Katsanos, K., and Tsolakis, J. Sirolimus-eluting versus bare
stents for bailout after suboptimal infrapopliteal angioplasty
for critical limb ischemia: 6-month angiographic results from
a nonrandomized prospective single-center study. J En-
dovasc Ther 12, 685, 2005.
42. Veldkamp, R.F., Valk, S.D., van Domburg, R.T., van Her-
werden, L.A., and Meeter, K. Mortality and repeat inter-
ventions up until 20 years after aorto-coronary bypass
surgery with saphenous vein grafts. A follow-up study of
1041 patients. Eur Heart J 21, 747, 2000.
43. Goldman, S., Zadina, K., Moritz, T., Ovitt, T., Sethi, G., Co-
peland, J.G., et al. Long-term patency of saphenous vein and
left internal mammary artery grafts after coronary artery
bypass surgery: results from a Department of Veterans
Affairs Cooperative Study. J Am Coll Cardiol 44, 2149, 2004.
44. Goldman, S., Sethi, G.K., Holman, W., Thai, H., McFalls, E.,
Ward, H.B., et al. Radial artery grafts vs saphenous vein
grafts in coronary artery bypass surgery: a randomized trial.
JAMA 305, 167, 2011.
45. Berry, C., Pieper, K.S., White, H.D., Solomon, S.D., Van de
Werf, F., Velazquez, E.J., et al. Patients with prior coronary
artery bypass grafting have a poor outcome after myocar-
dial infarction: an analysis of the VALsartan in acute
myocardial iNfarcTion trial (VALIANT). Eur Heart J 30,
1450, 2009.
114 TILLMAN ET AL.
46. Sanz-Ruiz, R., Ibanes, E.G., Arranz, A.V., Santos, M.E.F.,
Fernandez, P.L.S., and Fernandez-Aviles, F.F. Phases I–III
clinical trials using adult stem cells. Stem Cells Int 2010,
12, 2010.
47. Wollert, K.C., and Drexler, H. Cell therapy for the treatment
of coronary heart disease: a critical appraisal. Nat Rev Car-
diol 7, 204, 2010.
48. Lefevre, F., Aronson, N., Ziegler, K.M., Bonnell, C.J., and
Gere, M.A. Autologous Progenitor Cell Therapy for the
Treatment of Ischemic Heart Disease. TEC Assessment
Program, BlueCross BlueShield Association, Kaiser Perma-
nente Medical Care Program, 2008.
49. Gersh, B.J., Simari, R.D., Behfar, A., Terzic, C.M., and Terzic,
A. Cardiac cell repair therapy: a clinical perspective. Mayo
Clin Proc 84, 876, 2009.
50. Konstam, M.A., Kronenberg, M.W., Rousseau, M.F., Udel-
son, J.E., Melin, J., Stewart, D., et al. Effects of the angiotensin
converting enzyme inhibitor enalapril on the long-term
progression of left ventricular dilatation in patients with
asymptomatic systolic dysfunction. SOLVD (Studies of
Left Ventricular Dysfunction) Investigators. Circulation 88,
2277, 1993.
51. Hosoda, T., Kajstura, J., Leri, A., and Anversa, P. Mechan-
isms of myocardial regeneration. Circ J 74, 13, 2010.
52. Mosterd, A., and Hoes, A.W. Clinical epidemiology of heart
failure. Heart 93, 1137, 2007.
53. Cowie, M.R., and Zaphiriou, A. Management of chronic
heart failure. BMJ 325, 422, 2002.
54. de Giuli, F., Khaw, K.T., Cowie, M.R., Sutton, G.C., Ferrari,
R., and Poole-Wilso, P.A. Incidence and outcome of persons
with a clinical diagnosis of heart failure in a general practice
population of 696,884 in the United Kingdom. Eur J Heart
Fail 7, 295, 2005.
55. Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J.J.,
Ponikowski, P., Poole-Wilson, P.A., et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart
failure 2008: the Task Force for the diagnosis and treatment
of acute and chronic heart failure 2008 of the European So-
ciety of Cardiology. Developed in collaboration with the
Heart Failure Association of the ESC (HFA) and endorsed by
the European Society of Intensive Care Medicine (ESICM).
Eur J Heart Fail 10, 933, 2008.
56. Fonarow, G.C., Stevenson, L.W., Walden, J.A., Livingston,
N.A., Steimle, A.E., Hamilton, M.A., et al. Impact of a com-
prehensive heart failure management program on hospital
readmission and functional status of patients with advanced
heart failure. J Am Coll Cardiol 30, 725, 1997.
57. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M.,
Francis, G.S., Ganiats, T.G., et al. ACC/AHA 2005 Guideline
update for the diagnosis and management of chronic heart
failure in the adult: a report of the American College of
Cardiology/American Heart Association Task Force on
Practice Guidelines (writing committee to update the 2001
guidelines for the evaluation and management of heart
failure): developed in collaboration with the American Col-
lege of Chest Physicians and the International Society for
Heart and Lung Transplantation: endorsed by the Heart
Rhythm Society. Circulation 112, e154, 2005.
58. Rosenstrauch, D., Poglajen, G., Zidar, N., and Gregoric, I.D.
Stem cell therapy for ischemic heart failure. Tex Heart Inst J
32, 339, 2005.
59. Selvin, E., and Erlinger, T.P. Prevalence of and risk factors
for peripheral arterial disease in the United States. Results
from the National Health and Nutrition Examination Sur-
vey, 1999–2000. Circulation 110, 738, 2004.
Address correspondence to:
Alan Russell, PhD




Received: December 9, 2011
Accepted: September 10, 2012
Online Publication Date: November 20, 2012
MEETING THE NEED FOR REGENERATIVE THERAPIES 115
